This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
OncoMed Pharmaceuticals Inc. — whose wide-ranging deals around cancer stem cells once promised to bring in nearly $3 billion — will merge with a London biotech company for $57.4 million, according to terms of the transaction disclosed Wednesday.
The reverse merger between Redwood City-based OncoMed and Mereo BioPharma Grou p plc will give the London company a U.S. stock listing and seven experimental drugs.
If the deal closes as expected in first-half 2019, it would close the books on OncoMed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Mergers and Aquisitions | Pharmaceuticals | Stem Cell Therapy | Stem Cells